Kenneth Janzon
Chief Tech/Sci/R&D Officer chez Nordvacc Läkemedel AB
Fortune : 396 723 $ au 31/03/2024
Profil
Kenneth Janzon is the founder of Intervacc AB, which was founded in 2001.
He held the title of Independent Director at Intervacc AB.
Currently, Mr. Janzon is the Chief Technical Officer at Nordvacc Läkemedel AB.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INTERVACC AB
1,51% | 30/06/2023 | 1 146 500 ( 1,51% ) | 396 723 $ | 31/03/2024 |
Postes actifs de Kenneth Janzon
| Sociétés | Poste | Début |
|---|---|---|
Nordvacc Läkemedel AB
 Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The private company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Chief Tech/Sci/R&D Officer | - |
Anciens postes connus de Kenneth Janzon
| Sociétés | Poste | Fin |
|---|---|---|
| INTERVACC AB | Founder | 14/06/2018 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INTERVACC AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The private company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Distribution Services |
